Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Clinical trial NCT06854159 · RECRUITING

Trial details

NCT number: NCT06854159
Sponsor: University of California, Davis
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Start date: 2025-08-07
Primary completion: 2028-10-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.